Lantheus LNTH 深 滬
等待開盤 09-24 09:30:00 美东时间
99.979
-0.021
-0.02%
華盛通- 最 高100.28
- 今 開100.28
- 成交量 45.20万股
- 最 低 99.89
- 昨 收 100.00
- 總市值 65.29亿
- 52周最高 111.86
- 市盈率 靜 29.30
- 換手率 0.69%
- 52周最低 49.67
- 委 比 92.25%
- 總股本 6529.99万
- 歷史最高 126.8899
- 量 比 0.68
- 振 幅 0.39%
- 歷史最低 1.76
- 每 手 1
- 風險率 18.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lantheus gains approval of Bravnesta, generic competitor to Lutathera
The US FDA has granted final approval to Lantheus Holdings' (LNTH) Bravnesta (lutetium Lu 177 dotatate), a bioequivalent to Novartis' (NVS) radiopharmaceutical to Lutathera. Bravnesta is used for the ...
09-22 22:39
Lantheus withdraws, resubmits HSR filing for Curium acquisition
Lantheus Holdings (LNTH) said it has withdrawn and refiled its Hart-Scott-Rodino (HSR) Act pre-merger notification regarding its $8B acquisition of Curium. The withdrawal, done on Sept. 17, was done "...
09-22 05:35
Lantheus Merger Advances with Renewed Antitrust Review
Lantheus ( ($LNTH) ) has shared an update. On August 3, 2026, Lantheus Holdings...
09-22 04:59
朝阳门并购堂 | 2026年8月并购重组市场观察
（来源：中信建投证券投行委） 一、新增重组事件 （一）有研硅(688432.SH)停牌筹划重组 （二）雪天盐业(600929.SH) 停牌筹划重组 ...
09-16 17:09
Novartis' Lutathera now facing generic competition from Cirium's Bexlutry
The US FDA has approved Cirium's radioligand therapy Bexlutry (lutetium Lu 177 dotatate) for receptor-positive gastroenteropancreatic neuroendocrine tumors, the first such generic treatment approved f...
09-16 04:54
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
On Friday, the U.S. Food and Drug Administration (FDA) approved Lantheus Holdings Inc.’s (NASDAQ:LNTH) Tauklarify (florquinitau F 18 injection). Also known as MK-6240, this radiodiagnostic agent is designed for positron emission tomography (PET) scans of the brain in adult patients experiencing cogn...
08-15 00:11
Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ ...
08-14 20:02
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
Lantheus Holdings announced the U.S. FDA approval of TAUKLARIFY (florquinitau F 18 injection) for PET brain imaging in adults with cognitive impairment being evaluated for Alzheimer’s disease to identify tau neurofibrillary tangle pathology. The approval is supported by clinical studies showing high positive and negative percent agreement and strong inter-reader consistency. TAUKLARIFY is safe and effective, with common adverse reactions includin...
08-14 12:00
80亿核药世纪并购！两大核药巨头凑出完整产业链
（来源：求实药社） 核药行业的竞争攀升至全新维度。 8月3日，Curium官宣与Lantheus达成合并协议，交易总对价最高可达80亿美元，创下核药赛道有史...
08-13 17:26
财报速睇 | Lantheus 2026财年Q2营收3.88亿美元，同比增长2.7%；归母净利润0.75亿美元，同比下滑4.7%
华盛资讯8月6日讯，Lantheus公布2026财年Q2业绩，公司Q2营收3.88亿美元，同比增长2.7%，归母净利润0.75亿美元，同比下滑4.7%。
08-06 20:24
